Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
First received: January 30, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted
This research project addresses the hypothesis that a neurocognitive profile characterized by impairment of response inhibition and sustained attention may be a risk factor for smoking initiation and nicotine dependence among young women. Nicotine has short- term, facilitating effects on attention and response inhibition. Therefore, individuals who are impaired on cognitive functions such as these and initiate cigarette smoking may be more likely to maintain the habit and develop nicotine dependence. The research protocol specifically tests whether administration of nicotine to non-abstinent, regular cigarette smokers improves cognitive function in those domains where the participants had previously been shown to manifest performance deficits

Condition Intervention
Nicotine Dependence
Tobacco Use Disorder
Nicotine Use Disorder
Drug: Nicotine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers: A Double-Blind, Within-Subjects, Placebo-Controlled Study

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Neurocognitive functions

Estimated Enrollment: 40
Study Start Date: February 2007
Estimated Study Completion Date: April 2007

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Reported smoking cigarettes on a daily basis at the time of the original study and continue to smoke currently
  • Manifested poor performance on the MFFT (The neurocognitive test that yielded differences between smokers and non-smokers)
  • Competent and willing to give written informed consent

Exclusion Criteria:

  • Pregnancy, breast-feeding, non-use of contraception such that the possibility of pregnancy cannot be excluded
  • Intake of any medication that may potentially interact with nicotine.
  • Any current or past medical condition that represents a contra-indication to nicotine administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00429208

Contact: Avi Yakir, MD 00 972 2 6777184 yakir@hadassah.org.il
Contact: Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il

Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel
Contact: Arik Tzukert, DMD    00 972 2 6776095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    00 972 2 6777572    lhadas@hadassah.org.il   
Principal Investigator: Avi Yakir, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Avi Yakir, MD Hadassah Medical Organization
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00429208     History of Changes
Other Study ID Numbers: yakir@hmo 
Study First Received: January 30, 2007
Last Updated: January 30, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
Nicotine Dependence
Tobacco Use Disorder
Nicotine Use Disorder

Additional relevant MeSH terms:
Tobacco Use Disorder
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes
Substance-Related Disorders
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016